Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges
This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.
Read More
Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC
This episode highlights the significance of third-generation EGFR TKIs in delaying subsequent therapies for resectable, stage IB to IIIA EGFR-mutated NSCLC, explores the risks of postresection treatments for disease progression, and discusses treatment considerations for patients across different stages, focusing on the ADAURA trial outcomes for stage IB to IIIA NSCLC.
Read More
Although the NCCN guidelines recommend osimertinib as an adjuvant therapy option, what is your position on its use for completely resected stage IB to IIIA NSCLC with less common EGFR activating mutations, such as exon 20 insertion?
Read More
ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC
This episode reviews the key takeaways from the ADAURA trial, discusses strategies for protecting the CNS in EGFR-mutated NSCLC, and examines the impact ADAURA had on recurrence rates in patients with completely resected EGFR-mutated NSCLC who were previously treated with adjuvant chemotherapy.
Read More
Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA
This episode delves into expert perspectives on the safety and tolerability of combining osimertinib with chemotherapy in untreated, advanced EGFR-mutated NSCLC, resistance to third-generation EGFR TKIs, the superiority of concurrent versus sequential therapy from the FLAURA2 study, the role of ctDNA in managing additional EGFR mutations, and decision-making in utilizing FLAURA2 for treatment selection.
Read More
Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC
This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.
Read More
Closing Expert Perspectives on Treatment in Advanced NSCLC
Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.
Read More
Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape
Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.
Read More
Recent Advances in Treatment of ROS1-Rearranged NSCLC
Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.
Read More
Updates in Treatment of NSCLC with ALK Rearrangements
Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.
Read More
Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice
A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.
Read More
Recent Advances in Treatment of NSCLC with NTRK Fusions
Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.
Read More
Treatment of KRAS G12C Mutant NSCLC
Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.
Read More
Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC
Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.
Read More
Updates in Treatment of HER2 Mutant NSCLC
Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.
Read More
Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC
Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.
Read More
Updates in Treatment of NSCLC with Classical EGFR Mutations
A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.
Read More
Challenges Associated with Molecular Testing in NSCLC
A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.
Read More
Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?
A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.
Read More
Liquid Biopsies in the NSCLC Molecular Testing Algorithm
Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.
Read More
Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice
Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.
Read More
Dr. Husain on Ongoing Research Evaluating Plasma-Based Testing in Lung Cancer
March 25th 2020Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.
Read More
Dr. Husain on the Future of Monitoring T790M in Lung Cancer
March 24th 2017Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).
Read More
Dr. Husain on Monitoring the Emergence of T790M in Lung Cancer
January 6th 2017Hatim Husain, MD, assistant professor of Hematology-Oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR-mutated NSCLC.
Read More